Nil Albiol

Hematologist | CAR-T cell Unit | @hospitalclinic, Barcelona | Focused in #CART/#CARTcell, #CLL, #Richter and #Lymphoma

[Nil Albiol @nilalbiol]

It’s been a pleasure to share insights from our almost 10‑year #ARI0001 (var‑cel) program, tracing its development and compassionate use results, at the @tcddublin @stjamesdublin TSJCI 13th International Cancer Conference!
@hematoclinicbcn

[Valentín Ortiz-Maldonado @ValentinOrtizMD]

Honoured to see our phase 2 trial on Varnimcabtagene autoleucel for R/R B-ALL published in the March issue of @LancetHaem. A meaningful milestone for hospital-based innovation in cell therapy.

Pleased to discuss the study with Julio Delgado in the accompanying podcast!

[Valentín Ortiz-Maldonado @ValentinOrtizMD]

🚨New in Lancet Haematology:

CART19-BE-02 reports the multicentre phase 2 trial of varnimcabtagene autoleucel (var-cel), a hospital-based, point-of-care CD19 CAR T for adults with R/R B-cell precursor ALL.

https://t.co/OD0Q3M98Ud

🔓Free access link:
https://t.co/p3O7qOLrlm

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

This Guidelines paper recommends prioritizing CAR T-cell therapy over bispecific antibodies or ADCs for eligible relapsed/refractory myeloma patients, as prior use of certain agents may reduce CAR T-cell effectiveness. 

👉https://t.co/rh0KQXSbjS

[ACS Journal Cancer @JournalCancer]

The current findings suggest that nonhematologic AIDs are prevalent in patients with chronic lymphocytic leukemia, and these patients have a better prognosis than patients who have autoimmune cytopenia.

https://t.co/tSkDQRw6TY

@OncoAlert @miguel_argdtom @hematosantpau #leusm

[Miguel Argüello @miguel_argdtom]

Thrilled to share our new paper in Cancer on advances in CLL & Autoimmunity! 😊😊 Our comprehensive work dives into the clinical and immunologic alterations in these patients: epidemiology, prognosis, Th17/Treg cells... @gellc @hematosantpau @nilalbiol
https://t.co/p7yrGyNNNf

[Lymphoma Hub @lymphomahub]

CONGRESS | #ASH25 | PRESENTATION
@gabriel_brisou @paoli_calmettes shares results from a comparative analysis of axi-cel vs liso-cel as 2L therapy in real-world patients with R/R LBCL in France.
After PS-weighting, there was no significant difference in OS or PFS, however, axi-cel was associated with a higher incidence of ICANS, CRS, ICU transfers and NRM vs liso-cel.
Follow our live feed for more updates: https://t.co/QvRGEzgS3d
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content; a full list of supporters can be found on our website.
#lymphoma #lymsm #MedicalCongress

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #ASH25 | PRESENTATION
Aina Oliver-Caldes shares findings from a real-world study of patients with RRMM treated with ARI0002h (cesnicabtagene autoleucel) (N = 123).
ORR was 95%, MRG-neg rate was 91%. Any grade CRS was 63%; grade 3 CRS 1.6%. Grade 1-2 ICANS in 4% of patients, comparable to the pivotal clinical trial.
Follow our live feed for more updates: https://t.co/cPmhfLsCUj
Intended for HCPs only. This congress coverage is independently supported by pharmaceutical companies, who are allowed no influence on the content. A full list of supporters can be found on our website.
#mmsm #myeloma #MedicalCongress @ainitaoliver @hospitalclinic

[Hematologia Hospital Clínic Barcelona @hematoclinicbcn]

📣SAVE THE DATE

VII edición:

"Aspectos prácticos en aplicación clínica de terapia Chimeric Antigen Receptor T-Cell (CAR-T)".

📅23-24 Oct 2025

📍Facultat de Medicina de la Universitat de Barcelona

🗣️Información e inscripciones: https://t.co/egMD0jiil5…

[Kate Cwynarski @CwynKate]

Drug development in MZL: caring for the forgotten child

⁦⁦@BloodPortfolio⁩

⁦@c_thieblemont⁩
#Sylvain Carras
⁦@ComeBommier⁩ https://t.co/23Cnr2XoGr

[Côme Bommier @ComeBommier]

🇪🇸 var-cel in R/R FL

academic anti-CD19 CAR T-cells
N = 27
CRS all grades 55%, grade 3+ 4%
3-y PFS 81%

Worth reading @Hemasphere_EHA !

https://t.co/ucTt8LUyq8

[Nil Albiol @nilalbiol]

Our academic CAR-T (var-cel or ARI0001) from ⁦@hematoclinicbcn⁩ achieved similar efficacy to other CD19-directed products with a negligible ICANS incidence! It’s been a reality for almost 30 pts, most pf them remaining in CR to date. Congrats! https://t.co/Z8LeJSFd7r

[Nil Albiol @nilalbiol]

I will also present the results of a study evaluating the use of cell-free cfDNA MRD in CLL together with my great colleague @miguel_argdtom
No. 1430 #iwCLL2025

[Nil Albiol @nilalbiol]

Check out our poster on the results of varnimcabtagene autoleucel (ARI0001) in CLL and Richter’s transformation!
Poster no. 1905
#iwCLL2025

[Nil Albiol @nilalbiol]

Sure it is! Apply now!

[Côme Bommier @ComeBommier]

#CRTH is just the perfect place to learn how to design a credible trial, connect with talented hematologists, and benefit from the insights of experienced mentors.
We even take time to address work-life balance!

If you’re interested, do not hesitate: apply before it’s too late!

[Lymphoma Hub @lymphomahub]

CONGRESS | #SOHO2025 | PRESENTATION
@niravshahmd @MedicalCollege presents phase Ia results from the phase I NX-5948-301 trial of bexobrutideg (NX-5948) in patients with R/R CLL/SLL (N = 48).
Bexobrutideg was well tolerated, and responses were rapid, with an ORR of 80.9%, a median time to first response of 1.87 months.
Follow our live feed for more updates: https://t.co/Cwfu9pGqMX
#leusm #lymsm #MedicalCongress

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | #EHA2025 | POSTER
Juan Du, Shanghai Changzheng Hospital, presents updated phase I results on 1L BCMA-CD19 dual CAR-T therapy in transplant-eligible high-risk NDMM (N=22).
Median FU=37.1 months. High response rates: ORR and MRD-neg=100%; sCR=95%. Median DoR not reached. No Grade ≥3 CRS, ICANS or neurotoxicity.
Follow our live feed for more updates: https://t.co/4ZHzoNKDBS
#myeloma #mmsm #MedicalCongress

[NEJM @NEJM]

Two patients had autoimmune hemolytic anemia that relapsed after CD19 CAR T-cell therapy but responded rapidly to BCMA-targeted T-cell–engager therapy with remission, minimal side effects, and hematologic improvement. Learn more: https://t.co/Jhni7W8897

[Guillermo Ramil @guillermoramil]

Happy to present two posters about molecular MRD in AML at #EHA2025 in Milan. Check them out at today’s poster session!

[Nil Albiol @nilalbiol]

Congrats to everyone! Especially to @LeppaSM and @JulioDelgadoHem @hematoclinicbcn

[European Hematology Association @EHA_Hematology]

📢 EHA 2025 Board Election Results 📢

We are pleased to announce the results of the EHA 2025 Board elections. After a thorough and democratic process, we welcome our newly elected Board members, who will serve from 2025 to 2029, helping to shape the future of hematology and guide EHA’s mission forward.

We extend our gratitude to all candidates and members who participated in this important election. Your engagement strengthens our community and ensures continued progress in the field.

Join us in congratulating the new Board members! 🎉

#EHA2025 #BoardElections #HematologyLeadership